|
|
|
|
|
|
|
|
BioFirst Corporation was established on Nov. 7th, 2006. BioFirst is dedicated to research, develop, manufacturing, and marketing of innovative patented medical products. Untill, 2014, our Paid in Capital has reached USD 7.32 million dollars.Bio1st-owned technologies are exclusively authorized by local research organizations for global market. Vitreous Substitute is our current core R&D product pipeline authorized by National Health Research Institutes (NHRI). Vitreous Substitute is the first hydrogel product used in retinal detachment surgery. With its leading technology in the world, it is also named as the "Glory of Taiwan." Bio1st had already initiated constructions for a GMP premise. Its production base in Hsinchu Biomedical Science Park will be established for global market supply. We also licensed in ocular irrigating solutions from NHRI and a Nanomagnetic Drug Carrier Technology (drug controlled release platform) from National Chiao Tung University.BioFirst is also importer and distributor of foreign innovative products, and enters China Market through local distributors. BioFirst is establishing the foundation to market our products in global market in the future.
|
|
|
|
||
| 07/2014 | Obtained New Events GTSM (GreTai Securities Market) registration for approval on July 7th, start OTC trading of securities on July 15. | |
| 03/2014 |
Obtained official approval for Over The Counter Markettrading of securities on May 15th, GTSM ticker 6458. |
|
| 03/2014 |
Completed its first common stock share offering to employees and increased Capital to NT$227.89 M. |
|
| 05/2014 | Subvention grant received for the new anti-ADHD medication BLI-1008 from R&D project, Hsinchu Science Park Bureau, Ministry of Science and Technology. | |
|
|
02/2014 |
Completed Capital Increase to NT$215 million dollars (USD 7 million dollars). |
|
|
01/2014 |
Signed Distribution Agreement with Oriental Resources Development Limited to market wound dressing and sterilization products. |
|
|
12/2013 |
GluKopet A1c system received the first order from China. |
|
|
11/2013 |
Obtained TFDA approval for Clover A1c Self Glycosylated Hemoglobin Real-Time Detection System. |
|
|
11/2013 |
Obtained approval from SBIR of Ministry of Economic Affair (MOEA) for BLI-1003(BFC-1401) meeting GMP and GLP standard. 49% of total expenditure was granted. |
|
|
10/2013 |
Obtained Approval to establish GMP plant for Vitreous Substitute in Hsinchu Biomedical Science Park. |
|
|
|
|
|
|
07/2013 |
Signed exclusive distribution adreement with BioPredictive from France as its distributor in Taiwan. |
|
|
06/2013 |
Formed exclusive sales/marketing team, establish distribution channel. |
|
|
06/2013 |
Licence in drug carrier technilogy from Nation Chiao Tung University. |
|
|
05/2013 |
Signed distribution agreement with Infopia from Korea as the distributor in Taiwan and China for GlukoPetA1c animal hemoglobin detection system. |
|
|
02/2013 |
Patent for Vitreous Substitute approved in Taiwan. |
|
|
01/2013 |
Merged with Brisight Biomedical Corporation and obtained global rights for 3 patented technologies from National Health Research Institute (NHRI). |
|
|
01/2013 |
Brisight Biomedical Corporation's product, BFC-1401 obtained subvention from SBIR of MOEA. |
|
|
10/2012 |
Acquired Jun-Nuo Technology Ltd. and botained distribution right for 4 products. |
|
|
06/2012 |
Obtained patent approval for Vitreous Substitute in US. |
|
|
04/2012 |
Brisight Biomedical Corporation signed co-development contract with NHRI and obtained access to the facilities of the Division of Medical Engineering. |
|
|
02/2012 |
Brisight Biomedical Corporation moved into NHRI Incubation Center. |
| 11/2011 |
Magmedical Technologies Corporation recognized as Biotech and New Pharmaceutical Enterprise by Industrial Development Bureau of MOEA. |
|
| 01/2011 |
Brisight Biomedical Corporation obtained exclusive rights of three technologies from NHRI. |
|
| 06/2010 |
Invested in Brisight Biomedical Corporation and proceeded medical device development in eye care category. |
|
| 12/2009 |
Invested in Magmedical Technologies Corporation(MTC) to develop new drug formulation. |
|
| 09/2008 |
Collaborated with the Incubation Center of Fu Jen Catholic University for "Marketing Plan for Beauty Product Line". |
|
| 06/2008 |
Qualified Statute for Upgrading Industry-defined Start-Up Enterprise in Special technology Industry by MOEA. |
|
| 04/2008 |
Established sports & health management business and developed healthcare and beauty product lines. |
|
| 02/2007 |
Moved in NangKang Biotech Incubation Center of SMEA (Small and Medium Enterprise Administration), MOEA. |
|
| 11/2006 |
BioFirst Corporation Established. |
|
Major Events